Article
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
The Lancet. Oncology - 1 Mar 2024
Mahadeo Kris Michael, Baiocchi Robert, Beitinjaneh Amer, Chaganti Sridhar, Choquet Sylvain, Dierickx Daan, Dinavahi Rajani, Duan Xinyuan, Gamelin Laurence, Ghobadi Armin, Guzman-Becerra Norma, Joshi Manher, Mehta Aditi, Navarro Willis H, Nikiforow Sarah, O'Reilly Richard J, Reshef Ran, Ruiz Fiona, Spindler Tassja, Prockop Susan
Abstract excerpt
BACKGROUND: Survival in Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease following haematopoietic stem-cell transplant (HSCT) or solid organ transplant (SOT) is poor after failure of initial therapy, indicating an urgent need for therapies for this ultra-rare disease. With recent EU marketing authorisation, tabelecleucel is the first off-the-shelf, allogeneic, EBV-specific T-cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.